This early-phase trial tests the safety and tolerability of a new drug called GRT6019 in 24 healthy men. Participants receive multiple doses over 4 weeks and are monitored for side effects and how the drug moves through the body. The goal is to see if GRT6019 is safe enough to st…
Phase: PHASE1 • Sponsor: Grünenthal GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC